SEARCH

SEARCH BY CITATION

References

  • 1
    Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401407.
  • 2
    Sampogna F, Tabolli S, Söderfeldt B et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006; 154: 844849.
  • 3
    Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol 2010; 146: 891895.
  • 4
    Pathirana D, Ormerod AD, Saiag P et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl.2): 570.
  • 5
    Katugampola RP, Lewis VJ, Finlay AY. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007; 156: 945950.
  • 6
    Reich K, Ortonne J-P, Kerkmann U et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221: 172178.
  • 7
    Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534542.
  • 8
    Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 13671374.
  • 9
    Torii H, Nakagawa H, the Japanese infliximab study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 4049.
  • 10
    Torii H, Nakagawa H, the Japanese infliximab study investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol 2011; 38: 321334.
  • 11
    Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 15521563.
  • 12
    Wozel G, Klein E, Mrowietz U, Reich K, Sebastian M, Streit V. Scalp psoriasis. J Dtsch Dermatol Ges 2011; 9: 7074.
  • 13
    Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23(Suppl.1): 1521.
  • 14
    Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366372.
  • 15
    Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 16751684.
  • 16
    St Clair EW, Wagner CL, Fasanmade AA et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 14511459.
  • 17
    Rahman MU, Strusberg I, Geusens P et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 12331238.
  • 18
    Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009; 19: 478487.
  • 19
    Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol and Hepatol 2006; 4: 12481254.
  • 20
    Hibi T, Sakuraba A, Watanabe M et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with the clinical efficacy in Crohn’s disease. Inflamm Bowel Dis 2011; doi: 10.1002/ibd.21886 (in press).